TY - JOUR
T1 - Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia
AU - Ceolin, Valeria
AU - Cenna, Rosita
AU - Resente, Francesca
AU - Spadea, Manuela
AU - Fagioli, Franca
AU - Bertorello, Nicoletta
N1 - Publisher Copyright:
© 2021 Taylor & Francis Group, LLC.
PY - 2022
Y1 - 2022
N2 - A 12-year-old male being treated for a high-risk relapsed T-acute lymphoblastic leukemia presented progressive weakness and numbness of both legs after having received a chemotherapy regimen that included bortezomib. Diagnosis of acute Guillain-Barré syndrome-like inflammatory demyelinating polyneuropathy was made following clinical examination, cerebrospinal fluid analysis, electrodiagnostic studies, magnetic resonance imaging, and serum immunoglobulin antibodies to anti-ganglioside. Intravenous immunoglobulin treatment was started, resulting in complete clinical recovery. Although in rare cases, Guillain-Barré syndrome after bortezomib therapy has been reported; this paper suggests that GBS may occur when bortezomib is administered and high‑dose intravenous immunoglobulin lead to a resolution of the symptoms.
AB - A 12-year-old male being treated for a high-risk relapsed T-acute lymphoblastic leukemia presented progressive weakness and numbness of both legs after having received a chemotherapy regimen that included bortezomib. Diagnosis of acute Guillain-Barré syndrome-like inflammatory demyelinating polyneuropathy was made following clinical examination, cerebrospinal fluid analysis, electrodiagnostic studies, magnetic resonance imaging, and serum immunoglobulin antibodies to anti-ganglioside. Intravenous immunoglobulin treatment was started, resulting in complete clinical recovery. Although in rare cases, Guillain-Barré syndrome after bortezomib therapy has been reported; this paper suggests that GBS may occur when bortezomib is administered and high‑dose intravenous immunoglobulin lead to a resolution of the symptoms.
KW - Bortezomib
KW - case report
KW - Guillain-Barré syndrome
KW - relapsed lymphoblastic leukemia
KW - Magnetic Resonance Imaging
KW - Immunoglobulins, Intravenous/therapeutic use
KW - Bortezomib/adverse effects
KW - Humans
KW - Male
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
KW - Guillain-Barre Syndrome/chemically induced
KW - Child
UR - http://www.scopus.com/inward/record.url?scp=85112075736&partnerID=8YFLogxK
U2 - 10.1080/08880018.2021.1959691
DO - 10.1080/08880018.2021.1959691
M3 - Article
C2 - 34369835
AN - SCOPUS:85112075736
SN - 0888-0018
VL - 39
SP - 187
EP - 192
JO - Pediatric Hematology and Oncology
JF - Pediatric Hematology and Oncology
IS - 2
ER -